Loading...
Loading...
AmpliPhi BioSciences Corporation
APHB announces it has entered into
Collaboration and License Agreements with UK-based University of
Leicester to develop a novel bacteriophage therapy targeting Clostridium
difficile (C. difficile), a serious gastrointestinal
infection for which new treatments are urgently required.
Under the terms of the agreements, AmpliPhi will fund Dr Martha Clokie's
team at the University of Leicester to progress non-clinical studies of
bacteriophage products as an alternative to treating antibiotic
resistant infections caused by C. difficile bacteria. Evaluations
of the efficacy of bacteriophage therapy will be carried out at the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in